Spin-off from the Pasteur Institute, DIACCURATE is a late preclinical stage biotechnology company which develops “sole-in-class” therapeutics in oncology and immunotherapy.
Location: France, Ile-de-France, Paris
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | Truffle Ca... | truffle.co... |
Mentions in press and media 2
| Date | Title | Description |
| 08.09.2021 | DIACCURATE SAS : Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck | DGAP-News: DIACCURATE SAS / Key word(s): Miscellaneous Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck 08.09.2021 / 10:00 The issuer is solely responsible for the content of this announcement. Diaccurate ... |
| 12.01.2021 | DIACCURATE acquires BIOKINESIS to create a sole-in-class biotech player in oncology and immunotherapy | BIOKINESIS absorption by DIACCURATE occurred early December 2020Dr. Dominique BRIDON leads the new entityDIACCURATE is now developing 3 programs in cancer and immunotherapyDIACCURATE will be initiating a first clinical trial by early 2022 P... |